

QUEEN'S UNIVERSITY BELFAST

*Title of studentship	Implantable device for on-demand and controlled drug delivery to the eye
Value / what	Fully funded
is covered?	100% of UK/EU twitien fees neid and an annual stinged for UK residents only (living
	expenses), currently at f14 777
Awarding	DFE
body	
Number of studentships	
*Summarv	The number of people suffering from chronic ocular diseases are growing rapidly.
descriptive	Three big classes of eye diseases namely, glaucoma, age-related macular
text /	blindness in the UK. The current mode of treating these chronic diseases is not
Example of	patient friendly, as it requires frequent intervention either via injections in the eye or
research	drops. Despite the emergence of new drugs for treating retinal diseases, current
project	intervals. Likewise, patients need to take daily eve drops for several years – resulting
	in poor adherence. Therefore, there is urgent need to reduce the frequency of
	intraocular injections or eye drops and reduce their complications by developing
	this unmet need by developing a novel controlled release implantable drug delivery
	system that will enable localised and on-demand drug delivery to the eye in treating
	both front and back of the eye diseases.
	This collaborative project between School of Pharmacy and School of Electronics,
	Electrical Engineering & Computer Science will provide unique experience for the potential PhD student in the design development and characterisation of the novel
	on-demand drug delivery system that has potential to overcome current drug
	delivery challenges to the eye. The student will gain skills in the field of both
	(design and fabrication).
*Supervisor(s	Dr Raj Thakur, School of Pharmacy, QUB &
,	QUB
*Eligibility /	UK/EU only
residence	
Status	
Country	Northern Ireiand
*Start date	1 October 2019
and duration	Funding covers a three-year full-time PhD.

*Faculty	MHLS
*Research centre / School	School of Pharmacy
Subject area	Pharmaceutics, pharmaceutical technology, drug delivery and polymer science, MEMS
Candidate requirements / Key skills required for the post	Applicants should have a 1st or 2.1 honours degree (or equivalent) in a relevant subject. Relevant subjects include Pharmacy, Engineering, Molecular Biology, Pharmaceutical Sciences, Biochemistry, Biological/Biomedical Sciences, Chemistry, or a closely related discipline.
*Deadline for applications	7 <sup>th</sup> January 2019
*How to apply / contacts	Postgraduate Research applicants for Pharmacy who are interested in applying for a fully funded DFE studentship must have applied to Queen's, via the Direct Applications Portal, and submitted all required supporting documents by the closing date, which will be announced later in the Academic year. <u>https://dap.qub.ac.uk/portal/user/u_login.php</u>
Relevant links / more information	http://www.qub.ac.uk/schools/SchoolofPharmacy/Research/PostgraduatePositions / http://www.qub.ac.uk/schools/SchoolofPharmacy/Research/
	Supervisors https://pure.qub.ac.uk/portal/en/persons/thakur-raghu-raj-singh(608efb12-6fca- 4362-8f19-ba8b5cd97c07).html https://pure.qub.ac.uk/portal/en/persons/neil-mitchell(92b87334-623c-4147-97f2- 323acb523886).html
Keywords for search filters	Ocular drug delivery, drug delivery, controlled drug delivery, microelectronics, MEMS, protein delivery, 3D printing
Training provided through the research project	Training will be provided in the formulation, analysis and characterisation of polymeric systems. Furthermore, training will also be provided in the micro-fabrication and characterisation of MEMS-based devices and 3D-fabrication.
Expected impact activities	PI has significant experience in commercialisation activities of ocular drug delivery systems, combined with expertise of Co-PI in MEMS. The project aims to improve the health-related-quality-of-life of visually-impaired patients. Due to the projects much, greater scope as compared to current ophthalmic delivery systems, the technologies described here has the potential to make a significant and far-reaching impact in this field and place UK Research at the very forefront of developments.